Development of the anti-HER3 antibody therapy for esophageal squamous cell carcinoma.
| Project/Area Number |
24591936
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 食道扁平上皮癌 / 抗体療法 / HER3 / HER2 / 抗HER3抗体 |
|---|
| Outline of Final Research Achievements |
Relations on expressions among HER family (HER1, HER2, HER3) and antitumor effect of anti-HER3 antibody against different HER3-expressed cell clones of esophageal squamous cell carcinoma were investigated. We found HER3 expressions did not correlated with powers of antiproliferative activity, ADCC or proapototic activity induced by anti-HER3 antibody in any cell clones. In addition, correlation between HER1/HER2 and HER3 expressions was not found.
|
Report
(4 results)
Research Products
(8 results)
